AbbVie (id:8478 ABBV)
171.81 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/21/2024 1:56:42 PM)
Exchange open, closes in 2 hours 3 minutes
About AbbVie
Market Capitalization 296.46B
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| Headquarters (address) |
1 North Waukegan Road North Chicago 60064-6400 IL United States |
| Phone | 847 932 7900 |
| Website | https://www.abbvie.com |
| Employees | 50,000 |
| Sector | Healthcare |
| Industry | Drug Manufacturers General |
| Ticker | ABBV |
| Exchange | New York Stock Exchange |
| Currency | USD |
| 52 week range | 137.65 - 207.32 |
| Market Capitalization | 296.46B |
| Dividend yield forward | 3.70 % |
| Dividend yield forward United States (ID:6, base:1863) | 4.21 % |
| P/E trailing | 58.45 |
| P/E forward | 13.83 |
| Price/Sale | 5.34 |
| Price/Book | 49.15 |
| Beta | 0.613 |
| EPS | 2.87 |
| EPS United States (ID:6, base:3390) | 24.32 |
Dividend growth streak
AbbVie has raised their dividend 10.00 years in a row. This is above the 4.478497 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: AbbVie has raised their dividend 3.70 years in a row. This is below the 41113.895000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: AbbVie has raised their dividend 7.84 years in a row. This is below the 24.014500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: AbbVie has raised their dividend 10.52 years in a row. This is below the 12.586200 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: AbbVie has raised their dividend 13.98 years in a row. This is above the 10.156100 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: AbbVie has raised their dividend 213.59 years in a row. This is above the 146.967900 year average in the 'Drug Manufacturers General' industry
Dividend growth streak
AbbVie has raised their dividend 10.00 years in a row. This is above the 4.478497 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: AbbVie has raised their dividend 3.70 years in a row. This is below the 41113.895000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: AbbVie has raised their dividend 7.84 years in a row. This is below the 24.014500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: AbbVie has raised their dividend 10.52 years in a row. This is below the 12.586200 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: AbbVie has raised their dividend 13.98 years in a row. This is above the 10.156100 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: AbbVie has raised their dividend 213.59 years in a row. This is above the 146.967900 year average in the 'Drug Manufacturers General' industry